Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889909 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2SCD5GRM5SCD | |
| SCHEMBL2889908 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2SCD5GRM5SCD | |
| SCHEMBL13876925 | 0.90 | HCRTR1 (0.52) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL2897705 | 0.89 | USP30 (0.47) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL4146420 | 0.89 | USP30 (0.47) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL8230533 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL2898392 | 0.89 | GRM5 (0.44) | HCRTR1HCRTR2SCD5GRM5 | |
| SCHEMBL14387423 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2SCD5SCD | |
| SCHEMBL2898389 | 0.89 | GRM5 (0.44) | HCRTR1HCRTR2SCD5GRM5 | |
| SCHEMBL2898387 | 0.89 | GRM5 (0.44) | HCRTR1HCRTR2SCD5GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | HCRTR1 191/4885HCRTR2 96/4885SCD5 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.